YD Bio Ltd (YDES) AI Stock Analysis
YDES AI stock analysis summary
AI ResearchYD Bio Ltd (YDES) is a commercial-stage biopharmaceutical and healthcare products company based in Taiwan. Between FY2023 and FY2025, revenue expanded at a two-year compound annual growth rate of 30.6% to reach $596,817, while annual net income was -$8.3M. As of June 30, 2026, the company held $2.7M in cash and short-term investments against $5,002 in total debt.
- Market cap
- $419.3M
- Revenue (TTM)
- $1.2M
- P/E
- —
- 1Y return
- -68.6% S&P 500 16.8%
- Avg. target
- —
Bull case
- Quarterly revenue grew 314.9% year-over-year in the latest quarter ending June 30, 2025.
- The company maintained a net cash position of $2.7M with only $5,002 in total debt as of June 30, 2026.
- Revenue expanded at a two-year compound annual growth rate of 30.6% between FY2023 and FY2025.
Bear case
- Gross margin deteriorated from 43.8% in FY2023 to -7.1% in FY2025.
- Annual net losses widened to -$8.3M in FY2025 alongside a negative free cash flow of -$8.0M.
- The stock posted a 1-year return of -68.6%, trailing the S&P 500 1-year return of 16.8%.
What YD Bio does
YD Bio Limited is a biopharmaceutical company focusing on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. Its eye disease treatment lineup includes 3D LensMate Artificial Tears, 3D LensMate Eye Drops, and the developmental LSC Eye Drug/Injection for retinal and macular disorders. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens products. Additionally, the company supplies drugs and medical materials for clinical trials, operates DNA methylation-based oncology testing programs, and provides clinical trial supply chain services. Founded in 2013 and based in Taipei, Taiwan, it serves corporate and retail customers.
Growth and profitability
Revenue increased from $350,131 in FY2023 to $510,360 in FY2024, representing 45.8% growth, and rose 16.9% to $596,817 in FY2025. Gross margin contracted from 43.8% in FY2023 to 30.4% in FY2024 and stood at -7.1% in FY2025. Operating margin was -2.8% in FY2023, -286.5% in FY2024, and -883.3% in FY2025. Net income was $13,560 in FY2023, -$1.4M in FY2024, and -$8.3M in FY2025, as research and development expenses grew to $1.6M. For the trailing twelve months ended June 30, 2025, revenue was $1.2M, with quarterly revenue growth of 314.9% year-over-year and an operating margin of -382.1%.
Balance sheet and cash flow
As of June 30, 2026, YD Bio Ltd held $2.7M in cash and short-term investments, total debt of $5,002, and net cash of $2.7M. Shareholders' equity was $4.5M, total assets were $10.1M, and the current ratio was 5.23 with a debt-to-equity ratio of 0.00. In FY2025, operating cash flow was -$6.6M, free cash flow was -$8.0M, and capital expenditures were $1.4M.
Valuation and performance
YD Bio Ltd had a market capitalization of $419.3M and an enterprise value of $226.2M as of October 16, 2026. The stock traded at a price-to-sales multiple of 338.4x, an enterprise value-to-revenue multiple of 182.5x, and a price-to-book ratio of 51.1x. These multiples compare to a median price-to-sales ratio of 4.1x and an operating margin of 14.0% for its US-listed Healthcare peers. Over the past year, the stock returned -68.6%, trailing the S&P 500 return of 16.8%, and closed at $5.92, which was 1.3% above its 200-day average.
What analysts expect
No analyst ratings, price targets, or earnings estimates are available for YD Bio Ltd. The stock closed at $5.92 on October 16, 2026, within its 52-week trading range of $1.70 to $22.00. For the trailing twelve months, diluted earnings per share were -$0.04, following annual EPS of -$0.57 in FY2023 and -$1.13 in FY2024. Next earnings announcement dates and consensus estimates are not reported.
Key risks and what to watch
- Operating cash flow was -$6.6M in FY2025, which exceeds the company's cash and short-term investments of $2.7M as of June 30, 2026.
- Operating margin was -883.3% in FY2025 as research and development expenses rose to $1.6M.
- Insiders own 80.2% of the company, which may concentrate voting control among existing leadership.
- The stock trades at a price-to-sales ratio of 338.4x, well above the 4.1x median of its US-listed Healthcare peers.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this YDES AI stock analysis
This page is an AI-written research summary of YD Bio Ltd (YDES). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: YDES income statement, YDES balance sheet, YDES key metrics, YDES chart. See the YDES stock overview for the latest quote and news.
YDES AI stock analysis FAQ
What does YD Bio Ltd do?
YD Bio Ltd is a biopharmaceutical company that commercializes healthcare products, life science clinical services, and regulated diagnostics, including eye drops, artificial tears, and contact lenses.
Does YD Bio Ltd pay a dividend?
YD Bio Ltd does not pay a dividend.
How much cash and debt does YD Bio Ltd have?
As of June 30, 2026, YD Bio Ltd had $2.7M in cash and short-term investments and $5,002 in total debt, giving it a net cash balance of $2.7M.
How does YD Bio Ltd's valuation compare to its sector?
YD Bio Ltd trades at a price-to-sales multiple of 338.4x and an enterprise value-to-revenue multiple of 182.5x, compared to a median price-to-sales ratio of 4.1x for its US-listed Healthcare peers.